LONDON, April 1, 2015 /PRNewswire/ -- Non-Hodgkin
Lymphoma Therapeutics in Major Developed Markets to 2020 - New
Entrants and Promising Pipeline Widen Targeted and
Immunotherapeutic Treatment Options
Summary
GBI Research, a leading business intelligence provider, has
released its latest research report, "Non-Hodgkin Lymphoma
Therapeutics in Major Developed Markets to 2020 - New Entrants and
Promising Pipeline Widen Targeted and Immunotherapeutic Treatment
Options", which provides in-depth insight into the indication. It
provides estimates of market size for 2013 along with forecasts
until 2020 for the eight major developed markets, which comprises
the US, UK, France, Germany, Italy, Spain,
Japan and Canada. It also covers disease epidemiology,
treatment algorithms, treatment patterns, in-depth analysis of
clinical trials including failure rates and pipeline analysis, and
analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).
The value of the NHL market is expected to reach $9.2 billion by 2020 from $5.6 billion in 2013 at a modest Compound Annual
Growth Rate (CAGR) of 7.4%. The expected launch of promising drugs,
including novel small molecule inhibitors and next-generation
monoclonal antibodies, as well as the continued use of the current
blockbuster, Rituxan/Mabthera (rituximab), will be the key growth
drivers. The launch of a premium-priced novel glycol-engineered
antibody; obinutuzumab; the personalized vaccine dasiprotimut-T,
mTOR inhibitor everolimus, and several kinase inhibitors including
idelalisib and ibrutinib (which already gained FDA approval) are
expected to have a significant impact on the market size.
Additionally, the extension of indications of several already
marketed drugs such as Revlimid as a maintenance therapy for DLBCL,
Velcade as a front-line therapy for MCL and Adcetris as front-line
therapy for CD30 T-cell lymphoma, will fuel the growth during the
forecast period.
The emerging treatment challenges in the current treatment
landscape (which include, treatment of refractory/relapsed disease
and increasing rituximab resistance) are expected to be addressed
by the promising NHL pipeline. In spite of a slew of expected
approvals the market is set to increase a modest pace due to the
patent expiry of the gold-standard therapy during the forecast
period.
Scope
The report analyzes treatment usage patterns, market
characterization, the pipeline, and key licensing and
co-development deals in the eight major developed markets of the
US, UK, France, Germany, Italy, Spain,
Japan and Canada. It includes -
- A brief introduction to NHL, including the disease's
pathogenesis, etiology, diagnosis and treatment algorithms
- In-depth analysis of currently marketed drugs for NHL, examining
their safety, efficacy, treatment patterns and strengths/weaknesses
and including a heat map that compares the drugs in terms of safety
and efficacy
- A comprehensive review of the pipeline for NHL, including
individual analysis of a number of late-stage pipeline drugs that
are likely to enter the market during the forecast period; the
pipeline is analyzed on the basis of Phase distribution, molecule
type, program type, mechanism of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by
Phase, trial size, trial duration and program failure rate for each
molecule type
- Multi-scenario forecast data of the market to 2020, taking into
account how the market may be affected by the introduction of new
drugs, the expiry of key patents on current drugs and the changes
in disease epidemiology across the key developed markets
Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that
have occurred in the NHL market since 2006
Reasons to buy
The report will enhance your decision-making capability by allowing
you to -
- Understand the NHL pipeline and the factors that indicate that it
is becoming more innovative
- Examine detailed profiles of promising pipeline products and gain
an insight into how they are likely to compete in the market and
who their main competitors will be
- Follow the trends in NHL clinical trial size and duration in
relation to industry averages and assess the potential risk of
future developmental programs according to mechanism of action by
considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the NHL market
over the forecast period, identify which countries are expected to
make the biggest contribution to this growth, and devise a more
effective country strategy through an understanding of key drivers
and barriers in the NHL market
- Accelerate and strengthen your market position by identifying key
companies for strategic partnerships
Download the full report:
https://www.reportbuyer.com/product/2464380/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/non-hodgkin-lymphoma-therapeutics-in-major-developed-markets-to-2020---new-entrants-and-promising-pipeline-widen-targeted-and-immunotherapeutic-treatment-options-300060021.html
SOURCE ReportBuyer